Turnstone Biologics Corp. Common Stock Cash Flow-to-Debt Ratio
Turnstone Biologics Corp. Common Stock cash flow-to-debt ratio. Turnstone Biologics Corp. Common Stock (TSBX) has a Cash Flow-to-Debt Ratio of -0.68x as of June 2025, meaning its operating cash flow of $-4.30 Million could theoretically repay -1% of its total liabilities ($6.34 Million) in one year. Check TSBX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Turnstone Biologics Corp. Common Stock (2021–2024)
Cash flow-to-debt ratio of Turnstone Biologics Corp. Common Stock from 2021 to 2024. Historical debt coverage capacity for Turnstone Biologics Corp. Common Stock across 4 annual periods. Also explore net asset growth rate of Turnstone Biologics Corp. Common Stock to track the company's year-over-year net asset growth rate.
Turnstone Biologics Corp. Common Stock Cash Flow-to-Debt Ratio by Year (2021–2024)
Turnstone Biologics Corp. Common Stock cash flow-to-debt ratio by year from 2021 to 2024. Year-by-year debt coverage analysis for Turnstone Biologics Corp. Common Stock. For the full cash flow conversion analysis, see Turnstone Biologics Corp. Common Stock cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -7.78x | $-67.44 Million | $8.67 Million | ▼ -66.3% |
| 2023 | -4.68x | $-66.15 Million | $14.15 Million | ▼ -1323.9% |
| 2022 | -0.33x | $-71.06 Million | $216.41 Million | ▼ -93.7% |
| 2021 | -0.17x | $-45.63 Million | $269.10 Million | — |